Methamphetamine‐induced loss of striatal dopamine innervation in BDNF heterozygote mice does not further reduce D3 receptor concentrations
- 8 January 2004
- Vol. 52 (1) , 11-19
- https://doi.org/10.1002/syn.10309
Abstract
Depletion of dopamine (DA) reduces D3 receptor number, but D3 receptor expression is also regulated by brain-derived neurotrophic factor (BDNF). We took advantage of transgenic heterozygous BDNF mutant mice (+/−) to determine if reduced BDNF and loss of DA fibers produced by methamphetamine were additive in their impact on D3 receptor number. We assessed selective markers of the dopaminergic system including caudate-putamen DA concentrations and quantitative autoradiographic measurement of tyrosine hydroxylase (TH) levels, DA transporter (DAT), and DA D3 receptor binding between vehicle and methamphetamine-treated BDNF +/− and their wildtype (WT) littermate control mice. Caudate-putamen DA concentrations, TH and DAT levels were significantly reduced following methamphetamine treatment in both WT and BDNF +/− mice. The extent of methamphetamine-induced reduction in TH and DAT was greater for the WT than BDNF +/− mice and DAT levels were also decreased to a greater extent in nucleus accumbens of WT as compared to BDNF +/− mice. Lower D3 receptor existed in caudate-putamen and nucleus accumbens in BDNF +/− mice and these differences were not affected by methamphetamine treatment. Taken together, these results not only substantiate the importance of BDNF in controlling D3 receptor expression, but also indicate that a methamphetamine-induced depletion of DA fibers fails to produce an additive effect with lowered BDNF for control of D3 receptor expression. In addition, the reduction of D3 receptor expression is associated with a decreased neurotoxic response to methamphetamine in BDNF +/− mice. Synapse 52:11–19, 2004.Keywords
This publication has 49 references indexed in Scilit:
- Striatal dopamine output is compromised within +/? BDNF miceSynapse, 2001
- D2 but not D3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal periodSynapse, 2001
- Intravenous Brain-Derived Neurotrophic Factor Reduces Infarct Size and Counterregulates Bax and Bcl-2 Expression After Temporary Focal Cerebral IschemiaStroke, 2000
- Alterations in Nigrostriatal Dopaminergic Function within BDNF Mutant MiceExperimental Neurology, 1999
- Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosetsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
- Invited Review Free radicals and the pathobiology of brain dopamine systemsNeurochemistry International, 1998
- Role of Bcl‐2 in the Brain‐derived Neurotrophic Factor Survival ResponseEuropean Journal of Neuroscience, 1995
- Mice lacking brain-derived neurotrophic factor develop with sensory deficitsNature, 1994
- Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione SystemJournal of Neurochemistry, 1992
- Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine: I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine systemExperimental Neurology, 1991